Skip to main content


  • Meeting abstract
  • Open Access

OR13-005 – Investigation of clinical and laboratory significance of TNFRSF1A intron by reverse-phase protein microarray

  • 1,
  • 2,
  • 2,
  • 3,
  • 2,
  • 2 and
  • 2
Pediatric Rheumatology201311 (Suppl 1) :A267

  • Published:


  • Prednisolone
  • Peripheral Blood Mononuclear Cell
  • Etanercept
  • Anakinra
  • Acute Phase Response


Genetic analysis for autoinflammatory disease may reveal sequence changes of uncertain clinical significance. We describe investigation of a 26 year old with unexplained inflammatory symptoms with a novel intronic change in TNFRSF1A (intron 4 c.472+88 C>A) by examining reverse-phase protein microarray. In addition we describe clinical symptoms and response to anakinra and etanercept.


To assess whether this subject with intronic change had laboratory and clinical features which would confirm a diagnosis of TRAPS.


Clinical history was documented along with clinical response to prednisolone, anakinra and etanercept. Intracellular signaling pathways that govern inflammation associated with TNFRSF1A signaling pathways were examined in peripheral blood mononuclear cells (PBMC) using reverse-phase protein microarray. Profiles were compared between the subject with intronic change, C33Y TRAPS subjects and matched healthy control.


Clinical history confirmed some clinical features of TRAPS with fevers up to 40 degrees C from childhood and frequent episodes of myalgia, vomiting and abdominal pain lasting up to 4 weeks. On many occasions, however, symptoms were associated with normal CRP and SAA. Symptoms responded to oral prednisolone but no benefit occurred with anakinra. Subsequent treatment with etanercept resulted in less frequent and severe attacks.

Reverse phase protein microarray technology of signaling pathways has previously demonstrated that PBMC from patients with C33Y TRAPS show subtle upregulation of NF-kB, p38, MEK/ERK and JNK MAP kinase pathways, Phosphinositide 3 kinase, STAT3, JAK2/c-Src, GSK-3beta and transcription factors including ATF, Elk and Jun. The microarray from subject with intronic change did not show any significant variations compared to healthy control and did not resemble a C33Y TRAPS profile. However some proteins such as pERK1/2, pP38 and TRAF6 were downregulated in subject intron compared to control.


This subject with intronic change lacks some typical clinical features of TRAPS such as lack of acute phase response and responsiveness to anakinra. In addition protein array profile did not resemble that of C33Y TRAPS patient. This subject does however have a chronic recurrent febrile illness associated with TNFRSF1A intronic change and improvement on etanercept, suggesting other mechanisms could be implicated.

Disclosure of interest

None declared

Authors’ Affiliations

Clinical Immunology and Allergy, Nottingham University Hospitals NHS Trust, UK
Molecular Medical Science, University of Nottingham, Nottingham, UK
National Amyloidosis Centre, London, UK


© Drewe et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.